Core Insights - Krown Technologies and Quantum eMotion are advancing the development of quantum-secure cryptocurrency wallets, specifically the Qastle Quantum Hot Wallet and the Excalibur Quantum Cold Wallet, to protect digital assets from quantum computing threats [1][9] Group 1: Product Development - The Excalibur Cold Wallet is designed to be compact and offers universal compatibility, utilizing QeM's Quantum Random Number Generator (QRNG) technology, which reduces monetary loss risk by up to 98% compared to traditional cold wallets [3] - The Qastle Hot Wallet aims to provide quantum-grade security for online transactions, integrating advanced post-quantum algorithms to protect against quantum attacks [4] Group 2: Strategic Partnerships - The collaboration between Krown Technologies and Quantum eMotion is enhanced by a partnership with Esposito Intellectual Enterprises, which aims to accelerate the commercialization and visibility of the quantum-secure wallets [5][6] - Esposito Intellectual Enterprises leverages its extensive network to promote the adoption of Krown's Qastle and Excalibur wallets across various sectors [6] Group 3: Industry Context - The advancements in quantum cybersecurity are crucial as recent research indicates that quantum computers could potentially break traditional encryption more easily than previously thought [9]

会上，正泰集团董事、正泰新能源董事长、正泰安能董事长陆川回顾了正泰安能发展历程。陆川表 示，"136号文的发布，代表国家充分认可清洁能源主力电源地位，我们要坚持更安全、更便宜、更友 好、更绿色的能源发展方向，持续创新、降本、共赢，完成从C端分布式光伏领导者向全球综合能源服 务领导者的战略转型。" 6月13日消息，第三届综合能源服务创新发展大会暨正泰安能十周年战略焕新发布会12日在上海举行。 全国政协常委、中国民间商会副会长、正泰集团董事长南存辉在致辞中表示，"以光伏等为代表的具 有'更安全、更环保、更便宜、更便捷'的'四更'能源，将成为世界能源格局优化的主要力量。" 南存辉指出："正泰将继续牢牢锚定'双碳'目标，汇聚集团优势能力，支持正泰安能深化技术与模式创 新，在央国企、金融机构、代理商、供应商等广大生态合作伙伴协同支持下，构建'共创共享共赢'的综 合能源服务新生态，为推动能源转型、服务民生福祉，为经济社会全面绿色低碳转型贡献力量！" 据悉，成立十年来，正泰安能累计建成超180万座电站，每年可为全社会提供540亿度绿电，减排4320万 吨二氧化碳；累计发放收益近50亿元，带动农村超20万人就业。 正泰安能总 ...

Core Points - Spectral Medical Inc. held its Annual Meeting of shareholders on June 5, 2025, where all resolutions in the Management Information Circular were approved [1][2] Group 1: Election of Directors - Seven director nominees were elected with high approval rates, including Jan D'Alvise (99.78%), Jun Hayakawa (99.79%), and David W. Feigal, Jr. (99.67%) [3] Group 2: Appointment of Auditors - MNP LLP was re-appointed as the auditor of Spectral with 99.95% votes in favor [4] Group 3: Company Overview - Spectral is a Phase 3 company seeking U.S. FDA approval for its product Toraymyxin™ (PMX), a therapeutic hemoperfusion device for treating septic shock [4][5] - PMX has been approved for use in Japan and Europe, with over 360,000 applications to date [5] - The U.S. FDA granted Breakthrough Device Designation for PMX in July 2022 for endotoxic septic shock treatment [5] Group 4: Clinical Trials - The Tigris Trial is a confirmatory study comparing PMX in addition to standard care versus standard care alone, designed as a 2:1 randomized trial of 150 patients [6]

Core Insights - Mainz Biomed N.V. plans to provide an interim readout of its eAArly DETECT 2 feasibility study by the end of summer 2025, with top-line results expected in Q4 2025 [1][2] - The study aims to validate a next-generation colorectal cancer screening test that combines proprietary mRNA biomarkers, an AI-developed algorithm, and a FIT test on approximately 2,000 average-risk patients [1][3] - The company is on track to initiate its U.S. pivotal trial, ReconAAsense, in 2026 based on the outcomes of the eAArly DETECT 2 study [2][3] Study Details - The eAArly DETECT 2 study is expected to complete enrollment in the second half of 2025, targeting the reporting of top-line results by Q4 2025 [2] - The study will evaluate the effectiveness of five novel mRNA biomarkers acquired from Sherbrooke University in 2022, which have shown the ability to identify advanced adenomas and early-stage colorectal cancer [3] Company Mission - The company aims to advance its mission of eliminating colorectal cancer and reducing global cancer mortality rates through precise detection of advanced precancerous lesions and early-stage colorectal cancer [3]

TORONTO, May 16, 2025 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced that management will participate in a fireside chat at the 3rd Annual H.C. Wainwright BioConnect Investor Conference, on Tuesday, May 20, 2025 at 11:30 a.m. ET at the Nasdaq headquarters in New York City, New York. Investors interested in scheduling a meeting with the Company's management team sho ...

Core Insights - Spectral Medical Inc. has completed enrollment for its Tigris trial, a Phase III clinical trial evaluating PMX for endotoxic septic shock, with topline results expected in August 2025 [1][2][3] - The company has entered into a promissory note agreement with Vantive for up to US$10 million to support PMX commercialization [1][9] Clinical Development - The Tigris trial has enrolled a total of 157 patients, with 151 evaluable patients and 100 treated with PMX [6] - The data lock for the trial is expected to be completed in approximately 90 days, with topline results anticipated two weeks post-data lock [6] - The company is on track to submit clinical results to the FDA by the end of October 2025 [6] Financial Performance - Revenue for Q1 2025 was $572,000, a decrease of 14% from $668,000 in Q1 2024 [10] - Operating expenses increased significantly to $13,174,000, up 173% from $4,825,000 in the prior year, primarily due to non-cash fair value adjustments [11] - The company reported a loss of $12,605,000 for Q1 2025, compared to a loss of $4,160,000 in Q1 2024 [13] Balance Sheet and Financing - As of March 31, 2025, the company had cash of $1,670,000, down from $2,988,000 at the end of 2024 [14] - The promissory note with Vantive includes a four-year maturity and a payment-in-kind interest rate of 9% [15] Commercialization Activities - The company is collaborating with Vantive on post-approval marketing plans for PMX commercialization [15] - Vantive intends to submit a 510(k) application for its PrisMax System, which is expected to be the primary device used for PMX treatments upon commercial launch [15] Regulatory and Clinical Study Insights - The EDEN study, completed in Q4 2023, showed that patients with endotoxic septic shock had a significantly higher mortality rate of 60% compared to 14.1% for other septic shock patients [6] - The results from the EDEN study will inform discussions with the FDA regarding PMX labeling and the addressable population in the U.S. [6]

Core Viewpoint - Spectral Medical Inc. has secured a non-dilutive financing agreement with Vantive US Healthcare LLC for up to US$10 million to support the commercialization of its blood filtration therapy, Toraymyxin™ (PMX) [2][4][5]. Financing Details - The financing consists of a senior secured promissory note with a total principal amount of up to US$10 million, which can be drawn in up to four tranches [2][3]. - The first tranche of US$4 million was triggered on May 6, 2025, upon the execution of the agreement [4]. - The remaining tranches are contingent upon specific milestones outlined in the agreement [4]. Company Strategy and Milestones - The funds will support Spectral's evidence generation strategy and the path to commercialization of PMX, which is designed to remove endotoxin from the bloodstream in patients with sepsis [3][4]. - The company does not anticipate needing additional funding to meet key upcoming milestones, including the release of topline results and U.S. FDA submission [4]. Management Commentary - The CEO of Spectral expressed gratitude for the partnership with Vantive, emphasizing the non-dilutive nature of the funding and the alignment between the two companies [5]. Product Overview - PMX is a therapeutic hemoperfusion device that has been approved for use in Japan and Europe and has been utilized over 360,000 times [11]. - The device is currently seeking U.S. FDA approval and has received Breakthrough Device Designation for the treatment of endotoxic septic shock [11]. Clinical Trial Information - The Tigris Trial is a confirmatory study comparing PMX in addition to standard care versus standard care alone, designed as a 2:1 randomized trial involving 150 patients [12].

4月24日晚间，卫星化学（002648）(002648.SZ)发布2025年第一季度报告，受益于报告期内销售量价齐 升，公司一季度营业收入为123.29亿元，同比增长40.03%；归母净利润为15.68亿元，同比增长 53.38%；扣非后的归母净利润为16.92亿元，同比增长59.17%；随着本期利润增加，公司经营活动产生 的现金流量净额为15.99亿元，同比增长141.91%。 产品提质附加值持续提升 公司2025年一季度延续了2024年四季度(营收、归母净利润分别同比增长41.69%、75.09%)的良好增长势 头，体现了公司新产能持续释放增量。 SAP新产能有望抓住纸尿裤增长机遇 近期，纸尿裤线上增速有回暖，包括卫星化学在内的产业链企业关注度显著提升。卫星化学在2024年报 中指出，公司历时十余年自主研发与创新的高吸水性树脂装置2024年实现满负荷运行，实现打造民族品 牌的初衷，成为国内外知名品牌的供应商。 2025年一季度，公司将上述产能优势进一步发挥，并开发高附加值产品。公司在此前一季度业绩预告中 指出，公司保持生产装置"安、稳、长、满、优"运行，不断探索挖掘装置潜力的同时，部分生产装置通 过技术创 ...

Core Insights - Mainz Biomed has initiated the eAArly DETECT 2 study to evaluate its next-generation colorectal cancer test, aiming to confirm previous results in detecting advanced precancerous lesions [1][2][3] - The study will enroll approximately 2,000 average-risk patients and is expected to report top-line results in the fourth quarter of 2025 [1][2] - The company plans to finalize protocols for its U.S. pivotal study, ReconAAsense, based on the outcomes of the eAArly DETECT 2 study, with initiation targeted for 2026 [2] Group 1 - The eAArly DETECT 2 study aims to validate the effectiveness of five novel mRNA biomarkers acquired from Sherbrooke University in 2022, which can identify advanced adenomas and early-stage colorectal cancer [3] - The study integrates proprietary mRNA biomarkers, an AI-developed algorithm, and a FIT test to enhance diagnostic sensitivity and specificity for early-stage colorectal cancer [1][3] - The first patient has been enrolled, marking the formal commencement of the study after months of preparatory work [3] Group 2 - Mainz Biomed's flagship product, ColoAlert®, is a non-invasive early-detection diagnostic test for colorectal cancer, currently marketed across Europe [4] - The company is also developing PancAlert, an early-stage pancreatic cancer screening test based on real-time PCR multiplex detection of molecular-genetic biomarkers [4]